+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer Pain Management Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis

  • PDF Icon

    Report

  • 450 Pages
  • April 2023
  • Region: Global
  • Renub Research
  • ID: 5780825

Cancer Pain Management Market is valued at US$ 5.18 Billion in the year 2022

Global Cancer Pain Management Market is predicted to hit over US$ 7.80 Billion by 2030 according to the publisher. Pain is a common and dreaded symptom experienced by individuals undergoing cancer treatment and long-term cancer survivors. Cancer pain can result from the disease itself, its treatments, or a combination of both and it may be acute or chronic, with some individuals experiencing pain long after treatment has ended. The number of people living with cancer-related pain is on the rise, due to the increasing number of long-term cancer survivors and the growing prevalence of cancer in older populations worldwide. With advances in cancer treatments, people are now living longer with advanced cancer, further contributing to the growing number of individuals with cancer-related pain.



The growing incidence of cancer-related pain and the effects of the opioid epidemic on the management of chronic pain have renewed efforts to develop new pain medications that are not addictive, as well as non-drug therapies for managing chronic pain. There is increasing recognition of the need for greater accessibility to pain management medications, which is driving the consumption and acceptance of these drugs over other therapeutic options. Consequently, the high levels of awareness, ease of access, fast-acting nature, and cost-effectiveness of pain management medications have made them a preferred choice over other therapy options.


Cancer Pain Management Market is expanding growth at a CAGR of 5.25% during the forecast period 2022 to 2030


Despite the existing treatment options, the cancer pain management industry is constantly looking for newer and more effective ways to manage pain in cancer patients. Key manufacturers in the industry are exploring the use of the network model for research and development to come up with innovative treatment options. Ongoing research and development efforts help businesses analyze new treatment combinations and their effectiveness in pain management. There is a shift in the industry towards developing personalized drugs, biologics, and quick-dose lifestyle medicines, which make up over 70% of the medications currently in development. The focus is no longer solely on managing symptoms, but on amending the disease itself. Manufacturers are also moving away from chemical-based medications and towards biologic products-based therapeutics. Sympathetic administrative reform is also helping to facilitate the development of novel and effective pain management medications. The Cancer Pain Management Market is valued at US$ 5.18 Billion in the year 2022.


Targeted Therapies is Fastest growing segment in the Cancer Pain Management Industry


By Treatment, Cancer Pain Management Market is divided into Inhibitors, Surgery Immunotherapy, Radiotherapy, Hormone Therapy, Chemotherapy, Targeted Therapies, and Others. Targeted therapies are an important and rapidly evolving field in cancer treatment, and they may play a significant role in managing pain associated with cancer. Targeted therapies are medications that are specifically designed to target the molecular pathways involved in the growth and spread of cancer cells.

By inhibiting the activity of certain proteins or molecules that promote cancer cell growth, targeted therapies can help to reduce the size of tumors and slow down their growth. The advantage of these therapies is that they typically spare normal cells from damage. Targeted therapies may also be used in combination with other treatments, such as chemotherapy, radiation therapy, or surgery, to manage pain associated with cancer. The development of new targeted therapies is an active area of research within the cancer pain management industry, with the aim of improving outcomes and quality of life for cancer patients.


Opioids Reported Foremost Market Stake in 2023


By Drug Type, Cancer Pain Management Market is sub-divided into Opioids, Non-Opioids and Nerve Blockers. Opioids drug are a category of medications frequently utilized to manage pain in cancer patients. These drugs operate by binding to particular receptors in the brain and spinal cord, which can alleviate pain. Opioids are effective for treating both short-term and long-term pain, and they can be administered in various forms, including tablets, patches, and injections.

However, their use should be approached with caution and personalized to each patient's unique requirements and situation, as opioids have potential risks and side effects. Healthcare providers should collaborate closely with their patients to design a thorough pain management strategy that evaluates the advantages and disadvantages of all possible options. Despite their risks, opioids continue to play a vital role in the cancer pain management industry.


Lung Cancer is projected to dominate the Disease Indication segment of Pain Management Market Revenue


By Disease Indication, Cancer Pain Management Market is classified into Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer and Others. The lung cancer segment was the leading disease indication in the cancer pain market and is predicted to maintain its dominance throughout the forecast period. This is attributed to the rising incidence of lung cancer, high prevalence of pain associated with lung cancer, and the availability of effective cancer pain analgesics for treating lung cancer. However, the breast cancer segment is anticipated to experience significant market growth during the forecast period, owing to the increasing prevalence of breast cancer and greater adoption of pain analgesics in breast cancer treatment.


United States of America is estimated to have the Largest Market Share for Cancer Pain Management Market


By Country, Cancer Pain Management Market is break up into 10 major markets: United States, United Kingdom, Japan, France, Germany, Italy, Spain, Saudi Arabia, China and Korea. The cancer pain management industry in the United States is a crucial component of the global market. It is among the largest markets for cancer pain management worldwide, propelled by various factors such as the high incidence of cancer in the nation, increased awareness about the significance of pain management in cancer treatment, and access to advanced medical technologies and therapies. Furthermore, the market is reinforced by a well-established healthcare infrastructure, reimbursement policies, and government initiatives to enhance cancer care and pain management.

This industry is also highly dynamic, with a constant evolution of novel drugs and therapies, and has enormous growth potential in the upcoming years. As the importance of pain management in cancer care continues to gain recognition, and new drugs and therapies are developed, the United States cancer pain management market is poised for significant expansion.


Key Player Analysis


There are several leading competitors contending in Cancer pain management 10MM market. Some of the notable players in the industry include Daiichi Sankyo Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Orexo AB, Pfizer Inc, Teva Pharmaceutical Industries Limited, Sanofi, Johnson & Johnson and Eli Lilly.

The report “Cancer Pain Management 10MM Industry, Forecast By Treatment (Immunotherapy, Radiotherapy, Chemotherapy, Hormone Therapy, Targeted Therapies, Inhibitors, Surgery, Others), Drug Type (Opioids, Non-Opioids, Nerve Blockers), Disease Indication (Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, Others), Country (United States, United Kingdom, Japan, France, Germany, Italy, Spain, Saudi Arabia, China, Korea), Companies (Daiichi Sankyo Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Orexo AB, Pfizer Inc, Teva Pharmaceutical Industries Limited, Sanofi, Johnson & Johnson, Eli Lilly)” provides a detailed analysis of Cancer Pain Management 10MM Industry.


Treatment - Market has been covered from 8 viewpoints:


1. Immunotherapy
2. Radiotherapy
3. Chemotherapy
4. Hormone Therapy
5. Targeted Therapies
6. Inhibitors
7. Surgery
8. Others


Drug Type - Market has been covered from 3 viewpoints:


1. Opioids
2. Non-Opioids
3. Nerve Blockers


Disease Indication - Market has been covered from 6 viewpoints:


1. Lung Cancer
2. Colorectal Cancer
3. Breast Cancer
4. Prostate Cancer
5. Blood Cancer
6. Others


Country - Market has been covered from 10 viewpoints:


1. United States
2. United Kingdom
3. Japan
4. France
5. Germany
6. Italy
7. Spain
8. Saudi Arabia
9. China
10. Korea


Company Insights:


  • Overview
  • Recent Development
  • Financial Insight

Companies Covered:


1. Daiichi Sankyo Co., Ltd.
2. Hisamitsu Pharmaceutical Co., Inc.
3. Orexo AB
4. Pfizer Inc
5. Teva Pharmaceutical Industries Limited
6. Sanofi
7. Johnson & Johnson
8. Eli Lilly

Table of Contents

1. Introduction2. Research & Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. SWOT Analysis-Coronary Artery Disease Market
5.1 Strength
5.2 Weakness
5.3 Opportunity
5.4 Threat
6. Porter’s Five Forces
6.1 Bargaining Power of Buyers
6.2 Bargaining Power of Suppliers
6.3 Degree of Competition
6.4 Threat of New Entrants
6.5 Threat of Substitutes
7. Disease Background and Overview
7.1 Introduction
7.2 Etiology and Types
7.3 Cancer Pain Classification Systems
7.3.1 International Association for the Study of Pain (IASP) Taxonomy
7.3.2 ICD-11
7.3.3 Edmonton Classification System for Cancer Pain (ECS-CP)
7.4 Cancer Pain Pathophysiology
7.5 Cancer Pain Syndromes
7.6 Clinical Presentation and Assessment of Pain
8. Treatment and Management
8.1 NCCN Guidelines
8.2 ESMO Clinical Practice Guidelines (2018)
8.3 Spanish Guidelines
8.4 Canadian Recommendations for the Management of Breakthrough Cancer Pain (BTCP)
8.5 Multimodal Personalized Management of Cancer Pain
9. Cancer Pain Management Market - 10 Major Markets
10. Cancer Pain Epidemiology and Patient Population
10.1 Cancer Patients - 10 MM
10.2 Cancer Patients by Type, 2020 - 10 MM
10.3 Cancer Patients by Gender - 10 MM
10.4 Cancer Patients by Mortality Rate - 10 MM
11. Market Share Analysis - Global Cancer Pain Management
11.1 By Treatment
11.2 By Drug Type
11.3 By Disease Indication
11.4 By Country
12. Treatment - Global Cancer Pain Management 10MM
12.1 Immunotherapy
12.2 Radiotherapy
12.3 Chemotherapy
12.4 Hormone Therapy
12.5 Targeted Therapies
12.6 Inhibitors
12.7 Surgery
12.8 Others
13. Drug Type - Global Cancer Pain Management 10 MM
13.1 Opioids
13.2 Non-Opioids
13.3 Nerve Blockers
14. Disease Indication - Global Cancer Pain Management 10 MM
14.1 Lung Cancer
14.2 Colorectal Cancer
14.3 Breast Cancer
14.4 Prostate Cancer
14.5 Blood Cancer
14.6 Others
15. Country - Global Cancer Pain Management 10 MM
15.1 United States
15.1.1 By Cancer Incidence - Per Lakh of Total Population
15.1.2 By Gender - Cancer Patients
15.1.2.1 Male
15.1.2.2 Female
15.1.3 By Type - Cancer Patients, 2020
15.1.4 By Mortality - Cancer Patients
15.1.5 By Price Analysis - Cancer Pain Management Drug Price Per Capita
15.1.6 Market Analysis
15.2 United Kingdom
15.2.1 By Cancer Incidence - Per Lakh of Total Population
15.2.2 By Gender - Cancer Patients
15.2.2.1 Male
15.2.2.2 Female
15.2.3 By Type - Cancer Patients, 2020
15.2.4 By Mortality - Cancer Patients
15.2.5 By Price Analysis - Cancer Pain Management Drug Price Per Capita
15.2.6 Market Analysis
15.3 Japan
15.3.1 By Cancer Incidence - Per Lakh of Total Population
15.3.2 By Gender - Cancer Patients
15.3.2.1 Male
15.3.2.2 Female
15.3.3 By Type - Cancer Patients, 2020
15.3.4 By Mortality - Cancer Patients
15.3.5 By Price Analysis - Cancer Pain Management Drug Price Per Capita
15.3.6 Market Analysis
15.4 France
15.4.1 By Cancer Incidence - Per Lakh of Total Population
15.4.2 By Gender - Cancer Patients
15.4.2.1 Male
15.4.2.2 Female
15.4.3 By Type - Cancer Patients, 2020
15.4.4 By Mortality - Cancer Patients
15.4.5 By Price Analysis - Cancer Pain Management Drug Price Per Capita
15.4.6 Market Analysis
15.5 Germany
15.5.1 By Cancer Incidence - Per Lakh of Total Population
15.5.2 By Gender - Cancer Patients
15.5.2.1 Male
15.5.2.2 Female
15.5.3 By Type - Cancer Patients, 2020
15.5.4 By Mortality - Cancer Patients
15.5.5 By Price Analysis - Cancer Pain Management Drug Price Per Capita
15.5.6 Market Analysis
15.6 Italy
15.6.1 By Cancer Incidence - Per Lakh of Total Population
15.6.2 By Gender - Cancer Patients
15.6.2.1 Male
15.6.2.2 Female
15.6.3 By Type - Cancer Patients, 2020
15.6.4 By Mortality - Cancer Patients
15.6.5 By Price Analysis - Cancer Pain Management Drug Price Per Capita
15.6.6 Market Analysis
15.7 Spain
15.7.1 By Cancer Incidence - Per Lakh of Total Population
15.7.2 By Gender - Cancer Patients
15.7.2.1 Male
15.7.2.2 Female
15.7.3 By Type - Cancer Patients, 2020
15.7.4 By Mortality - Cancer Patients
15.7.5 By Price Analysis - Cancer Pain Management Drug Price Per Capita
15.7.6 Market Analysis
15.8 Saudi Arabia
15.8.1 By Cancer Incidence - Per Lakh of Total Population
15.8.2 By Gender - Cancer Patients
15.8.2.1 Male
15.8.2.2 Female
15.8.3 By Type - Cancer Patients, 2020
15.8.4 By Mortality - Cancer Patients
15.8.5 By Price Analysis - Cancer Pain Management Drug Price Per Capita
15.8.6 Market Analysis
15.9 China
15.9.1 By Cancer Incidence - Per Lakh of Total Population
15.9.2 By Gender - Cancer Patients
15.9.2.1 Male
15.9.2.2 Female
15.9.3 By Type - Cancer Patients, 2020
15.9.4 By Mortality - Cancer Patients
15.9.5 By Price Analysis - Cancer Pain Management Drug Price Per Capita
15.9.6 Market Analysis
15.10 Korea
15.10.1 By Cancer Incidence - Per Lakh of Total Population
15.10.2 By Gender - Cancer Patients
15.10.2.1 Male
15.10.2.2 Female
15.10.3 By Type - Cancer Patients, 2020
15.10.4 By Mortality - Cancer Patients
15.10.5 By Price Analysis - Cancer Pain Management Drug Price Per Capita
15.10.6 Market Analysis
16. Emerging Therapies
16.1 Key Cross Competition
16.2 Tetrodotoxin: WexPharma
16.2.1 Product description
16.2.2 Other developmental activities
16.2.3 Clinical development
16.2.4 Safety and efficacy
16.3 Resiniferatoxin: Sorrento Therapeutics
16.3.1 Product description
16.3.2 Other developmental activities
16.3.3 Clinical development
16.3.4 Safety and efficacy
16.4 QIXLEEF: Tetra Bio-Pharma
16.4.1 Product description
16.4.2 Other developmental activities
16.4.3 Clinical development
16.4.4 Safety and efficacy
17. Company Analysis
17.1 Daiichi Sankyo Co., Ltd.
17.1.1 Overview
17.1.2 Business Strategy
17.1.3 Financial Insight
17.2 Hisamitsu Pharmaceutical Co., Inc.
17.2.1 Overview
17.2.2 Business Strategy
17.2.3 Financial Insight
17.3 Orexo AB
17.3.1 Overview
17.3.2 Business Strategy
17.3.3 Financial Insight
17.4 Pfizer Inc
17.4.1 Overview
17.4.2 Business Strategy
17.4.3 Financial Insight
17.5 Teva Pharmaceutical Industries Limited
17.5.1 Overview
17.5.2 Business Strategy
17.5.3 Financial Insight
17.6 Sanofi
17.6.1 Overview
17.6.2 Business Strategy
17.6.3 Financial Insight
17.7 Johnson & Johnson
17.7.1 Overview
17.7.2 Business Strategy
17.7.3 Financial Insight
17.8 Eli Lilly
17.8.1 Overview
17.8.2 Business Strategy
17.8.3 Financial Insight
List of Figures:
Figure 01: Global - Cancer Pain Management Market (Billion US$), 2018 - 2022
Figure 02: Global - Forecast for Cancer Pain Management Market (Billion US$), 2023 - 2030
Figure 03: Treatment - Immunotherapy Market (Million US$), 2018 - 2022
Figure 04: Treatment - Forecast for Immunotherapy Market (Million US$), 2023 - 2030
Figure 05: Treatment - Radiotherapy Market (Million US$), 2018 - 2022
Figure 06: Treatment - Forecast for Radiotherapy Market (Million US$), 2023 - 2030
Figure 07: Treatment - Chemotherapy Market (Million US$), 2018 - 2022
Figure 08: Treatment - Forecast for Chemotherapy Market (Million US$), 2023 - 2030
Figure 09: Treatment - Hormone Therapy Market (Million US$), 2018 - 2022
Figure 10: Treatment - Forecast for Hormone Therapy Market (Million US$), 2023 - 2030
Figure 11: Treatment - Targeted Therapies Market (Million US$), 2018 - 2022
Figure 12: Treatment - Forecast for Targeted Therapies Market (Million US$), 2023 - 2030
Figure 13: Treatment - Inhibitors Market (Million US$), 2018 - 2022
Figure 14: Treatment - Forecast for Inhibitors Market (Million US$), 2023 - 2030
Figure 15: Treatment - Surgery Market (Million US$), 2018 - 2022
Figure 16: Treatment - Forecast for Surgery Market (Million US$), 2023 - 2030
Figure 17: Treatment - Others Market (Million US$), 2018 - 2022
Figure 18: Treatment - Forecast for Others Market (Million US$), 2023 - 2030
Figure 19: Drug Type - Opioids Market (Million US$), 2018 - 2022
Figure 20: Drug Type - Forecast for Opioids Market (Million US$), 2023 - 2030
Figure 21: Drug Type - Non-Opioids Market (Million US$), 2018 - 2022
Figure 22: Drug Type - Forecast for Non-Opioids Market (Million US$), 2023 - 2030
Figure 23: Drug Type - Nerve Blockers Market (Million US$), 2018 - 2022
Figure 24: Drug Type - Forecast for Nerve Blockers Market (Million US$), 2023 - 2030
Figure 25: Disease Indication - Lung Cancer Market (Million US$), 2018 - 2022
Figure 26: Disease Indication - Forecast for Lung Cancer Market (Million US$), 2023 - 2030
Figure 27: Disease Indication - Colorectal Cancer Market (Million US$), 2018 - 2022
Figure 28: Disease Indication - Forecast for Colorectal Cancer Market (Million US$), 2023 - 2030
Figure 29: Disease Indication - Breast Cancer Market (Million US$), 2018 - 2022
Figure 30: Disease Indication - Forecast for Breast Cancer Market (Million US$), 2023 - 2030
Figure 31: Disease Indication - Prostate Cancer Market (Million US$), 2018 - 2022
Figure 32: Disease Indication - Forecast for Prostate Cancer Market (Million US$), 2023 - 2030
Figure 33: Disease Indication - Blood Cancer Market (Million US$), 2018 - 2022
Figure 34: Disease Indication - Forecast for Blood Cancer Market (Million US$), 2023 - 2030
Figure 35: Disease Indication - Others Market (Million US$), 2018 - 2022
Figure 36: Disease Indication - Forecast for Others Market (Million US$), 2023 - 2030
Figure 37: United States - Cancer Incidence Per Lakh of Total Population (Number), 2018 - 2022
Figure 38: United States - Forecast for Cancer Incidence Per Lakh of Total Population (Number), 2023 - 2030
Figure 39: United States - Gender Cancer Patients (Thousand), 2018 - 2022
Figure 40: United States - Forecast for Gender Cancer Patients (Thousand), 2023 - 2030
Figure 41: United States - Male Cancer Patients (Thousand), 2018 - 2022
Figure 42: United States - Forecast for Male Cancer Patients (Thousand), 2023 - 2030
Figure 43: United States - Female Cancer Patients (Thousand), 2018 - 2022
Figure 44: United States - Forecast for Female Cancer Patients (Thousand), 2023 - 2030
Figure 45: United States - Mortality Cancer Patients (Thousand), 2018 - 2022
Figure 46: United States - Forecast for Mortality Cancer Patients (Thousand), 2023 - 2030
Figure 47: United States - Cancer Pain Management Drug Price Per Capita (US$), 2018 - 2022
Figure 48: United States - Forecast for Cancer Pain Management Drug Price Per Capita (US$), 2023 - 2030
Figure 49: United States - Cancer Pain Management Market (Million US$), 2018 - 2022
Figure 50: United States - Forecast for Cancer Pain Management Market (Million US$), 2023 - 2030
Figure 51: United Kingdom - Cancer Incidence Per Lakh of Total Population (Number), 2018 - 2022
Figure 52: United Kingdom - Forecast for Cancer Incidence Per Lakh of Total Population (Number), 2023 - 2030
Figure 53: United Kingdom - Gender Cancer Patients (Thousand), 2018 - 2022
Figure 54: United Kingdom - Forecast for Gender Cancer Patients (Thousand), 2023 - 2030
Figure 55: United Kingdom - Male Cancer Patients (Thousand), 2018 - 2022
Figure 56: United Kingdom - Forecast for Male Cancer Patients (Thousand), 2023 - 2030
Figure 57: United Kingdom - Female Cancer Patients (Thousand), 2018 - 2022
Figure 58: United Kingdom - Forecast for Female Cancer Patients (Thousand), 2023 - 2030
Figure 59: United Kingdom - Mortality Cancer Patients (Thousand), 2018 - 2022
Figure 60: United Kingdom - Forecast for Mortality Cancer Patients (Thousand), 2023 - 2030
Figure 61: United Kingdom - Cancer Pain Management Drug Price Per Capita (US$), 2018 - 2022
Figure 62: United Kingdom - Forecast for Cancer Pain Management Drug Price Per Capita (US$), 2023 - 2030
Figure 63: United Kingdom - Cancer Pain Management Market (Million US$), 2018 - 2022
Figure 64: United Kingdom - Forecast for Cancer Pain Management Market (Million US$), 2023 - 2030
Figure 65: Japan - Cancer Incidence Per Lakh of Total Population (Number), 2018 - 2022
Figure 66: Japan - Forecast for Cancer Incidence Per Lakh of Total Population (Number), 2023 - 2030
Figure 67: Japan - Gender Cancer Patients (Thousand), 2018 - 2022
Figure 68: Japan - Forecast for Gender Cancer Patients (Thousand), 2023 - 2030
Figure 69: Japan - Male Cancer Patients (Thousand), 2018 - 2022
Figure 70: Japan - Forecast for Male Cancer Patients (Thousand), 2023 - 2030
Figure 71: Japan - Female Cancer Patients (Thousand), 2018 - 2022
Figure 72: Japan - Forecast for Female Cancer Patients (Thousand), 2023 - 2030
Figure 73: Japan - Mortality Cancer Patients (Thousand), 2018 - 2022
Figure 74: Japan - Forecast for Mortality Cancer Patients (Thousand), 2023 - 2030
Figure 75: Japan - Cancer Pain Management Drug Price Per Capita (US$), 2018 - 2022
Figure 76: Japan - Forecast for Cancer Pain Management Drug Price Per Capita (US$), 2023 - 2030
Figure 77: Japan - Cancer Pain Management Market (Million US$), 2018 - 2022
Figure 78: Japan - Forecast for Cancer Pain Management Market (Million US$), 2023 - 2030
Figure 79: France - Cancer Incidence Per Lakh of Total Population (Number), 2018 - 2022
Figure 80: France - Forecast for Cancer Incidence Per Lakh of Total Population (Number), 2023 - 2030
Figure 81: France - Gender Cancer Patients (Thousand), 2018 - 2022
Figure 82: France - Forecast for Gender Cancer Patients (Thousand), 2023 - 2030
Figure 83: France - Male Cancer Patients (Thousand), 2018 - 2022
Figure 84: France - Forecast for Male Cancer Patients (Thousand), 2023 - 2030
Figure 85: France - Female Cancer Patients (Thousand), 2018 - 2022
Figure 86: France - Forecast for Female Cancer Patients (Thousand), 2023 - 2030
Figure 87: France - Mortality Cancer Patients (Thousand), 2018 - 2022
Figure 88: France - Forecast for Mortality Cancer Patients (Thousand), 2023 - 2030
Figure 89: France - Cancer Pain Management Drug Price Per Capita (US$), 2018 - 2022
Figure 90: France - Forecast for Cancer Pain Management Drug Price Per Capita (US$), 2023 - 2030
Figure 91: France - Cancer Pain Management Market (Million US$), 2018 - 2022
Figure 92: France - Forecast for Cancer Pain Management Market (Million US$), 2023 - 2030
Figure 93: Germany - Cancer Incidence Per Lakh of Total Population (Number), 2018 - 2022
Figure 94: Germany - Forecast for Cancer Incidence Per Lakh of Total Population (Number), 2023 - 2030
Figure 95: Germany - Gender Cancer Patients (Thousand), 2018 - 2022
Figure 96: Germany - Forecast for Gender Cancer Patients (Thousand), 2023 - 2030
Figure 97: Germany - Male Cancer Patients (Thousand), 2018 - 2022
Figure 98: Germany - Forecast for Male Cancer Patients (Thousand), 2023 - 2030
Figure 99: Germany - Female Cancer Patients (Thousand), 2018 - 2022
Figure 100: Germany - Forecast for Female Cancer Patients (Thousand), 2023 - 2030
Figure 101: Germany - Mortality Cancer Patients (Thousand), 2018 - 2022
Figure 102: Germany - Forecast for Mortality Cancer Patients (Thousand), 2023 - 2030
Figure 103: Germany - Cancer Pain Management Drug Price Per Capita (US$), 2018 - 2022
Figure 104: Germany - Forecast for Cancer Pain Management Drug Price Per Capita (US$), 2023 - 2030
Figure 105: Germany - Cancer Pain Management Market (Million US$), 2018 - 2022
Figure 106: Germany - Forecast for Cancer Pain Management Market (Million US$), 2023 - 2030
Figure 107: Italy - Cancer Incidence Per Lakh of Total Population (Number), 2018 - 2022
Figure 108: Italy - Forecast for Cancer Incidence Per Lakh of Total Population (Number), 2023 - 2030
Figure 109: Italy - Gender Cancer Patients (Thousand), 2018 - 2022
Figure 110: Italy - Forecast for Gender Cancer Patients (Thousand), 2023 - 2030
Figure 111: Italy - Male Cancer Patients (Thousand), 2018 - 2022
Figure 112: Italy - Forecast for Male Cancer Patients (Thousand), 2023 - 2030
Figure 113: Italy - Female Cancer Patients (Thousand), 2018 - 2022
Figure 114: Italy - Forecast for Female Cancer Patients (Thousand), 2023 - 2030
Figure 115: Italy - Mortality Cancer Patients (Thousand), 2018 - 2022
Figure 116: Italy - Forecast for Mortality Cancer Patients (Thousand), 2023 - 2030
Figure 117: Italy - Cancer Pain Management Drug Price Per Capita (US$), 2018 - 2022
Figure 118: Italy - Forecast for Cancer Pain Management Drug Price Per Capita (US$), 2023 - 2030
Figure 119: Italy - Cancer Pain Management Market (Million US$), 2018 - 2022
Figure 120: Italy - Forecast for Cancer Pain Management Market (Million US$), 2023 - 2030
Figure 121: Spain - Cancer Incidence Per Lakh of Total Population (Number), 2018 - 2022
Figure 122: Spain - Forecast for Cancer Incidence Per Lakh of Total Population (Number), 2023 - 2030
Figure 123: Spain - Gender Cancer Patients (Thousand), 2018 - 2022
Figure 124: Spain - Forecast for Gender Cancer Patients (Thousand), 2023 - 2030
Figure 125: Spain - Male Cancer Patients (Thousand), 2018 - 2022
Figure 126: Spain - Forecast for Male Cancer Patients (Thousand), 2023 - 2030
Figure 127: Spain - Female Cancer Patients (Thousand), 2018 - 2022
Figure 128: Spain - Forecast for Female Cancer Patients (Thousand), 2023 - 2030
Figure 129: Spain - Mortality Cancer Patients (Thousand), 2018 - 2022
Figure 130: Spain - Forecast for Mortality Cancer Patients (Thousand), 2023 - 2030
Figure 131: Spain - Cancer Pain Management Drug Price Per Capita (US$), 2018 - 2022
Figure 132: Spain - Forecast for Cancer Pain Management Drug Price Per Capita (US$), 2023 - 2030
Figure 133: Spain - Cancer Pain Management Market (Million US$), 2018 - 2022
Figure 134: Spain - Forecast for Cancer Pain Management Market (Million US$), 2023 - 2030
Figure 135: Saudi Arabia - Cancer Incidence Per Lakh of Total Population (Number), 2018 - 2022
Figure 136: Saudi Arabia - Forecast for Cancer Incidence Per Lakh of Total Population (Number), 2023 - 2030
Figure 137: Saudi Arabia - Gender Cancer Patients (Thousand), 2018 - 2022
Figure 138: Saudi Arabia - Forecast for Gender Cancer Patients (Thousand), 2023 - 2030
Figure 139: Saudi Arabia - Male Cancer Patients (Thousand), 2018 - 2022
Figure 140: Saudi Arabia - Forecast for Male Cancer Patients (Thousand), 2023 - 2030
Figure 141: Saudi Arabia - Female Cancer Patients (Thousand), 2018 - 2022
Figure 142: Saudi Arabia - Forecast for Female Cancer Patients (Thousand), 2023 - 2030
Figure 143: Saudi Arabia - Mortality Cancer Patients (Thousand), 2018 - 2022
Figure 144: Saudi Arabia - Forecast for Mortality Cancer Patients (Thousand), 2023 - 2030
Figure 145: Saudi Arabia - Cancer Pain Management Drug Price Per Capita (US$), 2018 - 2022
Figure 146: Saudi Arabia - Forecast for Cancer Pain Management Drug Price Per Capita (US$), 2023 - 2030
Figure 147: Saudi Arabia - Cancer Pain Management Market (Million US$), 2018 - 2022
Figure 148: Saudi Arabia - Forecast for Cancer Pain Management Market (Million US$), 2023 - 2030
Figure 149: China - Cancer Incidence Per Lakh of Total Population (Number), 2018 - 2022
Figure 150: China - Forecast for Cancer Incidence Per Lakh of Total Population (Number), 2023 - 2030
Figure 151: China - Gender Cancer Patients (Thousand), 2018 - 2022
Figure 152: China - Forecast for Gender Cancer Patients (Thousand), 2023 - 2030
Figure 153: China - Male Cancer Patients (Thousand), 2018 - 2022
Figure 154: China - Forecast for Male Cancer Patients (Thousand), 2023 - 2030
Figure 155: China - Female Cancer Patients (Thousand), 2018 - 2022
Figure 156: China - Forecast for Female Cancer Patients (Thousand), 2023 - 2030
Figure 157: China - Mortality Cancer Patients (Thousand), 2018 - 2022
Figure 158: China - Forecast for Mortality Cancer Patients (Thousand), 2023 - 2030
Figure 159: China - Cancer Pain Management Drug Price Per Capita (US$), 2018 - 2022
Figure 160: China - Forecast for Cancer Pain Management Drug Price Per Capita (US$), 2023 - 2030
Figure 161: China - Cancer Pain Management Market (Million US$), 2018 - 2022
Figure 162: China - Forecast for Cancer Pain Management Market (Million US$), 2023 - 2030
Figure 163: Korea - Cancer Incidence Per Lakh of Total Population (Number), 2018 - 2022
Figure 164: Korea - Forecast for Cancer Incidence Per Lakh of Total Population (Number), 2023 - 2030
Figure 165: Korea - Gender Cancer Patients (Thousand), 2018 - 2022
Figure 166: Korea - Forecast for Gender Cancer Patients (Thousand), 2023 - 2030
Figure 167: Korea - Male Cancer Patients (Thousand), 2018 - 2022
Figure 168: Korea - Forecast for Male Cancer Patients (Thousand), 2023 - 2030
Figure 169: Korea - Female Cancer Patients (Thousand), 2018 - 2022
Figure 170: Korea - Forecast for Female Cancer Patients (Thousand), 2023 - 2030
Figure 171: Korea - Mortality Cancer Patients (Thousand), 2018 - 2022
Figure 172: Korea - Forecast for Mortality Cancer Patients (Thousand), 2023 - 2030
Figure 173: Korea - Cancer Pain Management Drug Price Per Capita (US$), 2018 - 2022
Figure 174: Korea - Forecast for Cancer Pain Management Drug Price Per Capita (US$), 2023 - 2030
Figure 175: Korea - Cancer Pain Management Market (Million US$), 2018 - 2022
Figure 176: Korea - Forecast for Cancer Pain Management Market (Million US$), 2023 - 2030
Figure 177: Daiichi Sankyo Co., Ltd. - Global Revenue (Billion US$), 2018 - 2022
Figure 178: Daiichi Sankyo Co., Ltd. - Forecast for Global Revenue (Billion US$), 2023 - 2030
Figure 179: Hisamitsu Pharmaceutical Co., Inc. - Global Revenue (Billion US$), 2018 - 2022
Figure 180: Hisamitsu Pharmaceutical Co., Inc. - Forecast for Global Revenue (Billion US$), 2023 - 2030
Figure 181: Orexo AB - Global Revenue (Billion US$), 2018 - 2022
Figure 182: Orexo AB - Forecast for Global Revenue (Billion US$), 2023 - 2030
Figure 183: Pfizer Inc - Global Revenue (Billion US$), 2018 - 2022
Figure 184: Pfizer Inc - Forecast for Global Revenue (Billion US$), 2023 - 2030
Figure 185: Teva Pharmaceutical Industries Limited - Global Revenue (Billion US$), 2018 - 2022
Figure 186: Teva Pharmaceutical Industries Limited - Forecast for Global Revenue (Billion US$), 2023 - 2030
Figure 187: Sanofi - Global Revenue (Billion US$), 2018 - 2022
Figure 188: Sanofi - Forecast for Global Revenue (Billion US$), 2023 - 2030
Figure 189: Johnson & Johnson - Global Revenue (Billion US$), 2018 - 2022
Figure 190: Johnson & Johnson - Forecast for Global Revenue (Billion US$), 2023 - 2030
Figure 191: Eli Lilly - Global Revenue (Billion US$), 2018 - 2022
Figure 192: Eli Lilly - Forecast for Global Revenue (Billion US$), 2023 - 2030
List of Tables:
Table 01: Global - Cancer Patients - 10 MM Population (Number), 2018 - 2022
Table 02: Global - Forecast for Cancer Patients - 10 MM Population (Number), 2023 - 2030
Table 03: Global - Cancer Patients by Type, 2020 - 10 MM Population (Number), 2018 - 2022
Table 04: Global - Forecast for Cancer Patients by Type, 2020 - 10 MM Population (Number), 2023 - 2030
Table 05: Global - Cancer Patients by Male - 10 MM Population (Number), 2018 - 2022
Table 06: Global - Forecast for Cancer Patients by Male - 10 MM Population (Number), 2023 - 2030
Table 07: Global - Cancer Patients by Female - 10 MM Population (Number), 2018 - 2022
Table 08: Global - Forecast for Cancer Patients by Female - 10 MM Population (Number), 2023 - 2030
Table 09: Global - Cancer Patients by Mortality Rate - 10 MM Population (Number), 2018 - 2022
Table 10: Global - Forecast for Cancer Patients by Mortality Rate - 10 MM Population (Number), 2023 - 2030
Table 11: Global - Cancer Pain Management Market Share by Treatment (Percent), 2018 - 2022
Table 12: Global - Forecast for Cancer Pain Management Market Share by Treatment (Percent), 2022 - 2030
Table 13: Global - Cancer Pain Management Market Share by Drug Type (Percent), 2018 - 2022
Table 14: Global - Forecast for Cancer Pain Management Market Share by Drug Type (Percent), 2022 - 2030
Table 15: Global - Cancer Pain Management Market Share by Disease Indication (Percent), 2018 - 2022
Table 16: Global - Forecast for Cancer Pain Management Market Share by Disease Indication (Percent), 2022 - 2030
Table 17: Global - Cancer Pain Management Market Share by Country (Percent), 2018 - 2022
Table 18: Global - Forecast for Cancer Pain Management Market Share by Country (Percent), 2022 - 2030
Table 19: United States - Cancer Patients by Type, 2020
Table 20: Korea - Cancer Patients by Type, 2020
Table 21: United Kingdom - Cancer Patients by Type, 2020
Table 22: Japan - Cancer Patients by Type, 2020
Table 23: France - Cancer Patients by Type, 2020
Table 24: Germany - Cancer Patients by Type, 2020
Table 25: Italy - Cancer Patients by Type, 2020
Table 26: Spain - Cancer Patients by Type, 2020
Table 27: Saudi Arabia - Cancer Patients by Type, 2020
Table 28: China - Cancer Patients by Type, 2020

Companies Mentioned

  • Daiichi Sankyo Co., Ltd.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Orexo AB
  • Pfizer Inc
  • Teva Pharmaceutical Industries Limited
  • Sanofi
  • Johnson & Johnson
  • Eli Lilly

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Table Information